Vaccination with Plasmodium knowlesi AMA1 formulated in the novel adjuvant co-vaccine HT™ protects against blood-stage challenge in rhesus macaques
about
Production of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line systemProduction, Quality Control, Stability and Pharmacotoxicity of a Malaria Vaccine Comprising Three Highly Similar PfAMA1 Protein Molecules to Overcome Antigenic VariationHumoral immune responses to a single allele PfAMA1 vaccine in healthy malaria-naïve adultsAn empirical approach towards the efficient and optimal production of influenza-neutralizing ovine polyclonal antibodies demonstrates that the novel adjuvant CoVaccine HT™ is functionally superior to Freund's adjuvantCorrelation between Virus Replication and Antibody Responses in Macaques following Infection with Pandemic Influenza A Virus.Using infective mosquitoes to challenge monkeys with Plasmodium knowlesi in malaria vaccine studiesA malaria vaccine based on the polymorphic block 2 region of MSP-1 that elicits a broad serotype-spanning immune responseA PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys.Overcoming antigenic diversity by enhancing the immunogenicity of conserved epitopes on the malaria vaccine candidate apical membrane antigen-1.Low levels of polymorphisms and no evidence for diversifying selection on the Plasmodium knowlesi Apical Membrane Antigen 1 geneCrystal structure of Plasmodium knowlesi apical membrane antigen 1 and its complex with an invasion-inhibitory monoclonal antibody.Enhancing blockade of Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against PfRH5 and other merozoite antigens.Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?Recent advances in recombinant protein-based malaria vaccines.Diversity covering AMA1-MSP119 fusion proteins as malaria vaccines.Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infectionChallenges of assessing the clinical efficacy of asexual blood-stage Plasmodium falciparum malaria vaccinesPlasmodium knowlesi: a relevant, versatile experimental malaria model.Merozoite Surface Protein 1 from Plasmodium falciparum Is a Major Target of Opsonizing Antibodies in Individuals with Acquired Immunity against Malaria.Malaria vaccine adjuvants: latest update and challenges in preclinical and clinical research.Plasmodium vivax ligand-receptor interaction: PvAMA-1 domain I contains the minimal regions for specific interaction with CD71+ reticulocytes.Skin infection boosts memory B-cells specific for a cryptic vaccine epitope of group A streptococcus and broadens the immune response to enhance vaccine efficacy.Identification and validation of a novel panel of Plasmodium knowlesi biomarkers of serological exposure.malaria: current research perspectivesIn vitro invasion inhibition assay using antibodies against Plasmodium knowlesi Duffy binding protein alpha and apical membrane antigen protein 1 in human erythrocyte-adapted P. knowlesi A1-H.1 strainMalaria Vaccines: Recent Advances and New Horizons
P2860
Q26700012-D33D47E6-78A2-4605-BBAE-15AE790ED633Q28554439-35A06D0D-0A31-4913-8F73-F7A47BD15343Q28727698-AA0EAF94-F28D-4341-A193-B01F976581D7Q30352423-845C04E8-AB50-4A7A-9D3B-57D1E15579E6Q30381056-56970142-9BC7-43E4-A706-81EEE0673959Q33805512-73316AE1-623D-4321-92D9-B606CCA37D95Q34071439-27C4CF5E-10E8-4B58-A966-D787F967DC34Q34978590-B677D98F-F974-4D68-9CFE-7CEEC80EA9E6Q35079832-3A3D01AF-57D5-49B2-A1E9-9FE80B68AA62Q35604433-AB34A92E-B806-4B2E-830A-E4859D9266AEQ35606847-A8097221-35A2-4C88-A63A-4B5720462B73Q36384456-9A5B8BBA-1F24-4E39-8477-C0A0A9AD1D6FQ36391845-F1BA14ED-35A1-4CC3-BCE7-CAE26AC23AF4Q36394182-FB3779BA-5B60-4908-B527-A980E2693721Q36826984-FA468826-F56E-4251-BCE9-EF750028098DQ36903515-AA450B32-6C8B-46F1-B4A7-D24D08892F51Q37530299-A41BF4C3-565D-44E1-A41B-14E34FFB26DDQ38784765-1B883F9A-8D07-49E4-ADAD-D396DC34AB2EQ40055186-8186B99B-15B1-4626-97A2-B2D43392B6A5Q40752357-C7BA0A77-CAA8-43CB-B9E6-DA50861D4B57Q41566130-09260B91-94A9-401E-A853-D2BB14B7531AQ54218671-E368FE88-A84B-404A-A56B-B80EEBB33986Q55405299-9864C4F8-37D8-421E-86ED-2FDF59F3C404Q56344544-D3061533-F0AF-4530-850C-BCC7BC628F9DQ56355736-EAFC57B2-F332-4DBE-B1F4-40288D316D26Q56362064-C7DCD680-48D0-4BE0-8F39-BCC5E62A5F57
P2860
Vaccination with Plasmodium knowlesi AMA1 formulated in the novel adjuvant co-vaccine HT™ protects against blood-stage challenge in rhesus macaques
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Vaccination with Plasmodium kn ...... e challenge in rhesus macaques
@ast
Vaccination with Plasmodium kn ...... e challenge in rhesus macaques
@en
Vaccination with Plasmodium kn ...... e challenge in rhesus macaques
@nl
type
label
Vaccination with Plasmodium kn ...... e challenge in rhesus macaques
@ast
Vaccination with Plasmodium kn ...... e challenge in rhesus macaques
@en
Vaccination with Plasmodium kn ...... e challenge in rhesus macaques
@nl
prefLabel
Vaccination with Plasmodium kn ...... e challenge in rhesus macaques
@ast
Vaccination with Plasmodium kn ...... e challenge in rhesus macaques
@en
Vaccination with Plasmodium kn ...... e challenge in rhesus macaques
@nl
P2093
P2860
P50
P3181
P1433
P1476
Vaccination with Plasmodium kn ...... e challenge in rhesus macaques
@en
P2093
Alan W Thomas
Clemens H M Kocken
Leonie M van Duivenvoorde
Nicole van der Werff
Vanessa Walraven
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0020547
P407
P577
2011-01-01T00:00:00Z